COVID-19 Pandemic in Europe: Experiences in Switzerland, Austria and Germany

Many countries in Europe were severely affected by the COVID-19 pandemic, and in the last 12 months several clinical trials were initiated to better understand both the natural course of the disease and the best therapeutic options to be offered to patients in the different stages of the disease. This webinar will give an overview of the pandemic in Switzerland, Austria and Germany and the most relevant research activities which were implemented.



  • Martin Traber, MD, SGPM President and Global Medical Director Roche
  • PD Dr Ghazaleh Gouya Lechner, GPMed Board Member and Managing Director Gouya Insights

14:00-14:05 Introduction from the Chairs

14:05-14:25 Corona Immunitas – The National Research Program of the Swiss School of Public Health
Prof Dr Milo Puhan, Director of the Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland

14:25-14:45 Public Private Partnerships in Times of COVID-19. The Austrian Story
PD Dr Johannes Pleiner-Duxneuner, President GPMed and Medical Director Roche Austria

14:45-14:55 Introduction to DGPharMed and Brief Overview of the COVID-19 Pandemic in Germany
Simone Breitkopf, MD PhD, Medical Consulting, DGPharMed Board Member

14:55-15:05 Evidence Generation for Treatment Recommendations during the COVID-19 Pandemic
Friedhelm Leverkus, Director Health Technology Assessment & Outcomes Research, Pfizer and Member of the DGPharMed WG on Market Access

15:05-15:25 Panel Discussion

15:25-15:30 Conclusions
Dr Marco Romano, MD GFMD IFAPP President

Learning Outcomes

Participants to this webinar will:

  • Understand the activities of the Swiss School of Public Health regarding Corona Immunitas;
  • Appreciate the interesting public-private partnership activated in Austria;
  • Get information about the evolution of the pandemic in Germany and the treatment recommendations generated from several clinical trials.
Sun, 4.4.2021 | 14:00 - 15:30


Further details on the livestream